09.00

Welcome and introduction

Frédéric LIOTÉ (France), Hang-Korng EA (France), Fernando Perez-Ruiz (Spain)

09.05

Keynote introduction: trained immunity and inflammation

Mihai NETEA (The Netherlands)

09.35

New insights on epigenetic modulations of IL-1

Musa MHLANGA (The Netherlands)

10.35

Multiomics approaches in immune-related diseases 

Yang LI (Germany)

11.05

Metabolic reprogramming of bone marrow progenitors and atherosclerosis pathophysiology

Hafid AIT-OUFELLA (France)

13.20

Repurposing drugs to counteract the pathological responses of chondrocytes to BCP crystals

Tim WELTING (The Netherlands)

13.45

Energy metabolism in arterial calcification.

Claudia GOETTSCH (Germany)

14.10

Urate is associated with both calcification and total atherosclerotic burden in coronary arteries: results from the SCAPIS study

Panagiota Drivelegka (Sweden)

14.20

Association between recent gout flare and hospitalisation for heart failure in people with gout in England. A nested case-control study

Abhishek Abhishek (UK)

14.30

Inverse association between coronary artery calcification and plasma pyrophosphate: systemic deficiency and local compensation

Flora SZERI (Hungary)

14.40

Oxidative Stress and Cardiovascular Comorbidities in Gout: The Diagnostic Value of Allantoin and the Allantoin/Uric Acid Ratio

Blanka Stiburkova (Czech Republic)

15.10

Mineralisation in the eyes of people with rare and not-so-rare diseases: What is the overlap between PXE and AMD?

Imre Lengyel (UK)

15.35

Meniscus calcification and calcification formation mechanisms

Jessica BERTRAND (Germany)

16.00

Targeting Vascular Calcification in Progeria: A New Therapeutic Strategy

Sara TALLÓN-LORENZO (Spain)

16.10

The role of osmolarity and LRRC8A channel in cartilage homeostasis and osteoarthritis

Yasmine SEDJAÏ (France)

16.20

Chronic Fructose Consumption Drives Vascular Calcification Through Imbalance in ATP/Pyrophosphate Homeostasis

Alicia FLORES-ROCO (Spain)

16.30

Targeted Demineralization of Sub-RPE Calcifications using Anti-Elastin DTPA-HSA Nanoparticles in a Progeroid Mouse Model

Frank RUTSCH (Germany)

16.40

Distribution of calcium pyrophosphate crystal deposits on whole-body low-dose ct scan

Bùi HOÀNG ANH (France)

16.50

Opportunistic screening for calcium pyrophosphate crystal deposition using abdomino-pelvic CT-scan

Thomas HUET (France)

17.00

Calcified crystal-containing extracellular vesicles stimulate chondrocyte calcification in vitro

Andrea SCHWAB (Germany)

17.10

CPP disease and therapeutic perspectives 

Augustin LATOURTE (France)

08.45

Welcome & introduction

Alexander SO (Switzerland), Tristan PASCART (France)

09.00

Genetics of Kidney Traits: Update from the CKDGen Consortium

Anna KÖTTGEN (Germany)

09.30

Pleiotropic Benefits of SGLT2 Inhibitors and Novel Anti-Obesity Medications for Hyperuricemia and Gout

Chio YOKOSE (USA)

10.00

The genetic basis of CPPD disease in 2026

Tony MERRIMAN (New Zealand, USA)

10.50

Update on Gut Microbiota in Hyperuricemia and Gout

Robert TERKELTAUB (USA)

11.15

Pollutants and gout

Pascal RICHETTE (France)

11.40

Treat-to-target continuation of urate-lowering therapy versus a urate-lowering therapy discontinuation attempt strategy in gout patients in remission (GO TEST Finale): a pragmatic open label randomised superiority trial

Iris Rose PEETERS (The Netherlands)

11.50

Multi-omic analysis reveals new mechanisms underlying inflammation and resolution of gout flares

Brenda KISCHKEL (The Netherlands)

12.00

Characterizations of giant multinucleated cells phenotype and formation in gouty tophus

Charles LEROY (France)

13.30

Allopurinol hypersensitivity: how to avoid and how to manage after? 

Abhishek ABHISHEK (UK)

14.00

Cardiovascular implication of “asymptomatic” hyperuricemia: its it time to change the paradigm?

Claudio BORGHI (Italy)

14.50

Epigenetic clocks indicate accelerated aging in individuals with hyperuricemia and patients with gout

Medeea BADII (Romania)

15.00

Do uric acid crystals activate the NRRP3 inflammasome?

Radomir SLOMINSKI (USA)

15.10

Co-administration of mycophenolate mofetil with pegloticase yielded similar clinical outcomes as the co-administration of methotrexate with pegloticase in patients with uncontrolled gout

Brian LAMOREAUX (USA)

15.20

MSU crystal-Specific Regulation of Previously Uncharacterized Proteins in the PBMC Secretome

Nils ASMANN (The Netherlands)

15.30

Evidence from New Pragmatic Trials on Treat-to-Target Urate-Lowering Therapy in Gout

Hyon CHOI (USA)

15.45

The tophus revisited

Hang-Korng EA (France)